×
About 47,519 results

ALLMedicine™ Fatty Liver Center

Research & Reviews  22,753 results

The Emerging Role of B Cells in the Pathogenesis of NAFLD.
https://doi.org/10.1002/hep.31889
Hepatology (Baltimore, Md.); Barrow F, Khan S et. al.

May 7th, 2021 - Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of abnormal liver function worldwide. NAFLD refers to a group of liver conditions ranging from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), which i...

Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑as...
https://doi.org/10.3892/mmr.2021.12126
Molecular Medicine Reports; Wang W, He Y et. al.

May 6th, 2021 - Metabolic dysfunction‑associated fatty liver disease (MAFLD) is a serious threat to human health. Parthenolide (PAR) displays several important pharmacological activities, including the promotion of liver function recovery during hepatitis. The ai...

Circulating microRNA‑135a‑3p in serum extracellular vesicles as a potential biological ...
https://doi.org/10.3892/mmr.2021.12137
Molecular Medicine Reports; Jiang H, Qian Y et. al.

May 6th, 2021 - Non‑alcoholic fatty liver disease (NAFLD) is a widespread threat to human health. However, the present screening methods for NAFLD are time‑consuming or invasive. The present study aimed to assess the potential of microRNAs (miRNAs/miRs) in serum ...

Comparative transcriptomic analysis reveals an association of gibel carp fatty liver wi...
https://doi.org/10.1186/s12864-021-07621-2 10.1093/gigascience/giy111 10.1038/s42003-020-1094-y 10.1111/raq.12183 10.1016/S0044-8486(01)00526-9 10.3389/fphys.2018.00283 10.1016/S0044-8486(01)00700-1 10.1016/j.cbpa.2019.01.013 10.1046/j.1365-2761.1998.00089.x 10.3389/fmars.2020.00363 10.1016/j.fsi.2020.06.025 10.1002/hep.27284 10.1038/s41598-017-18324-8 10.1111/anu.12951 10.1016/j.fsi.2019.04.060 10.1007/s11427-010-0092-6 10.1016/j.aaf.2017.04.003 10.1002/9781119120759 10.1038/s41437-017-0049-7 10.1007/s10126-019-09930-w 10.1038/nmeth.1226 10.1186/s13059-016-0881-8 10.1016/S0021-9258(19)77928-9 10.1074/jbc.M709654200 10.1016/S1388-1981(00)00044-5 10.2183/pjab.85.12 10.1093/nar/gkaa970 10.1038/cdd.2015.158 10.1016/j.tcb.2015.10.014 10.1073/pnas.1100891108 10.1002/pmic.201800311 10.1016/j.cell.2013.12.010 10.1038/ncb3064 10.3390/ijms21144908 10.1038/s41586-019-1705-2 10.1101/gad.314674.118 10.1038/nchembio.2239 10.1016/j.bbrc.2016.08.124 10.1016/j.celrep.2020.02.049 10.3892/ol.2018.8447 10.1016/j.molcel.2018.10.042 10.1016/S0891-5849(00)00319-1 10.1016/S1096-4959(03)00149-0 10.2331/fishsci.65.796 10.1016/j.biomaterials.2016.03.036 10.1210/en.2015-1480 10.1111/j.1365-2095.2007.00507.x 10.1016/j.cell.2012.03.042 10.1007/s10565-019-09496-2 10.1038/s41419-019-1678-y 10.1016/j.freeradbiomed.2017.01.020 10.3390/ani10040628 10.1016/j.fsi.2018.10.023 10.1016/j.fsi.2020.09.036 10.18632/oncotarget.5162 10.1016/j.biopha.2018.11.030 10.1016/j.ejcb.2019.151058 10.1080/01621459.2015.1110523 10.1002/cphy.c120006 10.4238/2012.June.15.2 10.1186/1476-4598-8-117 10.1007/s11427-015-4801-z 10.1371/journal.pone.0225186 10.1371/journal.pone.0149378 10.1016/j.phrs.2020.104919 10.7554/eLife.02523 10.1016/j.tips.2017.02.005 10.1016/j.mce.2006.09.014 10.1186/s12864-018-4823-6 10.1007/BF00316069 10.1038/nprot.2013.055 10.1371/journal.pone.0010308 10.1128/JVI.06282-11 10.1038/nmeth.3317 10.1038/nmeth.1923 10.1186/1471-2105-12-323 10.1186/s13059-014-0550-8 10.1186/gb-2010-11-10-r106 10.1101/gr.1239303 10.1007/978-0-387-49317-6 10.2144/98242pf02 10.1186/s12864-017-3945-6 10.1186/s12864-019-5777-z
BMC Genomics; Zhang XJ, Zhou L et. al.

May 6th, 2021 - Fatty liver has become a main problem that causes huge economic losses in many aquaculture modes. It is a common physiological or pathological phenomenon in aquaculture, but the causes and occurring mechanism are remaining enigmatic. Each three li...

Obesity and Liver Cancer in Japan: A Comprehensive Review.
https://doi.org/10.21873/anticanres.14999
Anticancer Research; Nishikawa H, Fukunishi S et. al.

May 6th, 2021 - Lifestyle-related factors play a major role in the development of cancer. In recent years, obesity has become widespread in the world and has attracted attention not only as a cause of diabetes mellitus and atherosclerotic diseases but also as a f...

see more →

Guidelines  57 results

Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
https://pubmed.ncbi.nlm.nih.gov/33694066/
Hepatology International; Guerreiro GTS

Mar 9th, 2021 - Cardiovascular disease (CVD) is the leading cause of death among individuals with non-alcoholic fatty liver disease (NAFLD). Recently, NAFLD was renamed metabolic-associated fatty liver disease (MAFLD). This study aimed to compare cardiovascular r...

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achie...
https://doi.org/10.1053/j.gastro.2020.11.051
Gastroenterology Younossi ZM, Corey KE et. al.

Dec 11th, 2020 - Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with global public health impact affecting more than 25% of the global population. NAFLD is associated with significant morbidity and mortality from cirrhosis, h...

Latin American Association for the study of the liver (ALEH) practice guidance for the ...
https://doi.org/10.1016/j.aohep.2020.09.006
Annals of Hepatology; Arab JP, Dirchwolf M et. al.

Oct 8th, 2020 - Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20-30% of the general population. Furthermore, its prevalence is predicted to increase ex...

Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes
https://pubmed.ncbi.nlm.nih.gov/32586479/
Clinics in Geriatric Medicine; Mantovani A

Apr 16th, 2020 - Nonalcoholic fatty liver disease (NAFLD) is common in older patients with type 2 diabetes. In older patients with type 2 diabetes, the presence of NAFLD is associated with a higher risk of hepatic (eg, nonalcoholic steatohepatitis, cirrhosis, and ...

Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052356/
Frontiers in Pharmacology; Gisondi P,et al

Feb 24th, 2020 - Psoriasis is a chronic, systemic immune-mediated disease characterized by development of erythematous, indurated, scaly, pruritic plaques on the skin. Psoriasis is frequently associated to comorbidities, including psoriatic arthritis, cardiovascul...

see more →

Clinicaltrials.gov  23,561 results

The Emerging Role of B Cells in the Pathogenesis of NAFLD.
https://doi.org/10.1002/hep.31889
Hepatology (Baltimore, Md.); Barrow F, Khan S et. al.

May 7th, 2021 - Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of abnormal liver function worldwide. NAFLD refers to a group of liver conditions ranging from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), which i...

Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑as...
https://doi.org/10.3892/mmr.2021.12126
Molecular Medicine Reports; Wang W, He Y et. al.

May 6th, 2021 - Metabolic dysfunction‑associated fatty liver disease (MAFLD) is a serious threat to human health. Parthenolide (PAR) displays several important pharmacological activities, including the promotion of liver function recovery during hepatitis. The ai...

Circulating microRNA‑135a‑3p in serum extracellular vesicles as a potential biological ...
https://doi.org/10.3892/mmr.2021.12137
Molecular Medicine Reports; Jiang H, Qian Y et. al.

May 6th, 2021 - Non‑alcoholic fatty liver disease (NAFLD) is a widespread threat to human health. However, the present screening methods for NAFLD are time‑consuming or invasive. The present study aimed to assess the potential of microRNAs (miRNAs/miRs) in serum ...

Comparative transcriptomic analysis reveals an association of gibel carp fatty liver wi...
https://doi.org/10.1186/s12864-021-07621-2 10.1093/gigascience/giy111 10.1038/s42003-020-1094-y 10.1111/raq.12183 10.1016/S0044-8486(01)00526-9 10.3389/fphys.2018.00283 10.1016/S0044-8486(01)00700-1 10.1016/j.cbpa.2019.01.013 10.1046/j.1365-2761.1998.00089.x 10.3389/fmars.2020.00363 10.1016/j.fsi.2020.06.025 10.1002/hep.27284 10.1038/s41598-017-18324-8 10.1111/anu.12951 10.1016/j.fsi.2019.04.060 10.1007/s11427-010-0092-6 10.1016/j.aaf.2017.04.003 10.1002/9781119120759 10.1038/s41437-017-0049-7 10.1007/s10126-019-09930-w 10.1038/nmeth.1226 10.1186/s13059-016-0881-8 10.1016/S0021-9258(19)77928-9 10.1074/jbc.M709654200 10.1016/S1388-1981(00)00044-5 10.2183/pjab.85.12 10.1093/nar/gkaa970 10.1038/cdd.2015.158 10.1016/j.tcb.2015.10.014 10.1073/pnas.1100891108 10.1002/pmic.201800311 10.1016/j.cell.2013.12.010 10.1038/ncb3064 10.3390/ijms21144908 10.1038/s41586-019-1705-2 10.1101/gad.314674.118 10.1038/nchembio.2239 10.1016/j.bbrc.2016.08.124 10.1016/j.celrep.2020.02.049 10.3892/ol.2018.8447 10.1016/j.molcel.2018.10.042 10.1016/S0891-5849(00)00319-1 10.1016/S1096-4959(03)00149-0 10.2331/fishsci.65.796 10.1016/j.biomaterials.2016.03.036 10.1210/en.2015-1480 10.1111/j.1365-2095.2007.00507.x 10.1016/j.cell.2012.03.042 10.1007/s10565-019-09496-2 10.1038/s41419-019-1678-y 10.1016/j.freeradbiomed.2017.01.020 10.3390/ani10040628 10.1016/j.fsi.2018.10.023 10.1016/j.fsi.2020.09.036 10.18632/oncotarget.5162 10.1016/j.biopha.2018.11.030 10.1016/j.ejcb.2019.151058 10.1080/01621459.2015.1110523 10.1002/cphy.c120006 10.4238/2012.June.15.2 10.1186/1476-4598-8-117 10.1007/s11427-015-4801-z 10.1371/journal.pone.0225186 10.1371/journal.pone.0149378 10.1016/j.phrs.2020.104919 10.7554/eLife.02523 10.1016/j.tips.2017.02.005 10.1016/j.mce.2006.09.014 10.1186/s12864-018-4823-6 10.1007/BF00316069 10.1038/nprot.2013.055 10.1371/journal.pone.0010308 10.1128/JVI.06282-11 10.1038/nmeth.3317 10.1038/nmeth.1923 10.1186/1471-2105-12-323 10.1186/s13059-014-0550-8 10.1186/gb-2010-11-10-r106 10.1101/gr.1239303 10.1007/978-0-387-49317-6 10.2144/98242pf02 10.1186/s12864-017-3945-6 10.1186/s12864-019-5777-z
BMC Genomics; Zhang XJ, Zhou L et. al.

May 6th, 2021 - Fatty liver has become a main problem that causes huge economic losses in many aquaculture modes. It is a common physiological or pathological phenomenon in aquaculture, but the causes and occurring mechanism are remaining enigmatic. Each three li...

Obesity and Liver Cancer in Japan: A Comprehensive Review.
https://doi.org/10.21873/anticanres.14999
Anticancer Research; Nishikawa H, Fukunishi S et. al.

May 6th, 2021 - Lifestyle-related factors play a major role in the development of cancer. In recent years, obesity has become widespread in the world and has attracted attention not only as a cause of diabetes mellitus and atherosclerotic diseases but also as a f...

see more →

News  1,129 results

Look Beyond Liver Biopsy for NAFLD Diagnosis
https://www.medscape.com/viewarticle/950690

May 5th, 2021 - Nonalcoholic fatty liver disease (NAFLD) was present in approximately two-thirds of patients who did not undergo a liver biopsy. These patients were more likely to be non-White and older, as well as have normal ALT levels, which shows potential ga...

Bariatric Surgery May Cut Cancer in Obesity With Liver Disease
https://www.medscape.com/viewarticle/948869

Apr 6th, 2021 - In a large cohort of insured working adults with severe obesity and nonalcoholic fatty liver disease (NAFLD), among those who underwent bariatric surgery, the rate of incident cancer was lower during a 10-month median follow-up period. The rate wa...

Coffee Could Be the Secret Weapon Against NAFLD
https://www.medscape.com/viewarticle/948829

Apr 5th, 2021 - Treatment of obesity through exercise and diet is unquestionably the foundation of care for patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH). But drinking at least several cups of coffee a day makes for ad...

NAFLD Tied to Risk of Gastrointestinal, Lung, Breast, and Gynecological Cancers
https://www.medscape.com/viewarticle/948122

Mar 28th, 2021 - (Reuters Health) - People with non-alcoholic fatty liver disease (NAFLD) are at increased risk of developing several types of extrahepatic cancers, a meta-analysis of observational cohort studies suggests. Researchers examined data from 10 studies...

Neoadjuvant Chemo for Intrahepatic Cholangiocarcinoma May Prolong Life
https://www.medscape.com/viewarticle/947254

Mar 11th, 2021 - NEW YORK (Reuters Health) - For patients with intrahepatic cholangiocarcinoma (ICC), the benefits of neoadjuvant chemotherapy (NAC) may extend beyond downstaging borderline resectable disease to improved overall survival, according to a small retr...

see more →

Patient Education  19 results see all →